Rationale for targeting complement in COVID‐19
Abstract A novel coronavirus, SARS‐CoV‐2, has recently emerged in China and spread internationally, posing a health emergency to the global community. COVID‐19 caused by SARS‐CoV‐2 is associated with an acute respiratory illness that varies from mild to the life‐threatening acute respiratory distres...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2020-07-01
|
| Series: | EMBO Molecular Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.15252/emmm.202012642 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849235101662052352 |
|---|---|
| author | Anastasia Polycarpou Mark Howard Conrad A Farrar Roseanna Greenlaw Giorgia Fanelli Russell Wallis Linda S Klavinskis Steven Sacks |
| author_facet | Anastasia Polycarpou Mark Howard Conrad A Farrar Roseanna Greenlaw Giorgia Fanelli Russell Wallis Linda S Klavinskis Steven Sacks |
| author_sort | Anastasia Polycarpou |
| collection | DOAJ |
| description | Abstract A novel coronavirus, SARS‐CoV‐2, has recently emerged in China and spread internationally, posing a health emergency to the global community. COVID‐19 caused by SARS‐CoV‐2 is associated with an acute respiratory illness that varies from mild to the life‐threatening acute respiratory distress syndrome (ARDS). The complement system is part of the innate immune arsenal against pathogens, in which many viruses can evade or employ to mediate cell entry. The immunopathology and acute lung injury orchestrated through the influx of pro‐inflammatory macrophages and neutrophils can be directly activated by complement components to prime an overzealous cytokine storm. The manifestations of severe COVID‐19 such as the ARDS, sepsis and multiorgan failure have an established relationship with activation of the complement cascade. We have collected evidence from all the current studies we are aware of on SARS‐CoV‐2 immunopathogenesis and the preceding literature on SARS‐CoV‐1 and MERS‐CoV infection linking severe COVID‐19 disease directly with dysfunction of the complement pathways. This information lends support for a therapeutic anti‐inflammatory strategy against complement, where a number of clinically ready potential therapeutic agents are available. |
| format | Article |
| id | doaj-art-92ff360d09bb43c098725e7b4e0899cb |
| institution | Kabale University |
| issn | 1757-4676 1757-4684 |
| language | English |
| publishDate | 2020-07-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | EMBO Molecular Medicine |
| spelling | doaj-art-92ff360d09bb43c098725e7b4e0899cb2025-08-20T04:02:55ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842020-07-0112811510.15252/emmm.202012642Rationale for targeting complement in COVID‐19Anastasia Polycarpou0Mark Howard1Conrad A Farrar2Roseanna Greenlaw3Giorgia Fanelli4Russell Wallis5Linda S Klavinskis6Steven Sacks7MRC Centre of Transplantation, Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, Guy's Hospital, King's College LondonMRC Centre of Transplantation, Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, Guy's Hospital, King's College LondonMRC Centre of Transplantation, Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, Guy's Hospital, King's College LondonMRC Centre of Transplantation, Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, Guy's Hospital, King's College LondonMRC Centre of Transplantation, Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, Guy's Hospital, King's College LondonDepartment of Respiratory Science and Infection, Leicester Institute of Chemical and Structural Biology, University of LeicesterDepartment of Infectious Diseases, School of Immunology and Microbial Sciences, Guy's Hospital, King's College LondonMRC Centre of Transplantation, Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, Guy's Hospital, King's College LondonAbstract A novel coronavirus, SARS‐CoV‐2, has recently emerged in China and spread internationally, posing a health emergency to the global community. COVID‐19 caused by SARS‐CoV‐2 is associated with an acute respiratory illness that varies from mild to the life‐threatening acute respiratory distress syndrome (ARDS). The complement system is part of the innate immune arsenal against pathogens, in which many viruses can evade or employ to mediate cell entry. The immunopathology and acute lung injury orchestrated through the influx of pro‐inflammatory macrophages and neutrophils can be directly activated by complement components to prime an overzealous cytokine storm. The manifestations of severe COVID‐19 such as the ARDS, sepsis and multiorgan failure have an established relationship with activation of the complement cascade. We have collected evidence from all the current studies we are aware of on SARS‐CoV‐2 immunopathogenesis and the preceding literature on SARS‐CoV‐1 and MERS‐CoV infection linking severe COVID‐19 disease directly with dysfunction of the complement pathways. This information lends support for a therapeutic anti‐inflammatory strategy against complement, where a number of clinically ready potential therapeutic agents are available.https://doi.org/10.15252/emmm.202012642complement proteinsCOVID‐19lectin pathwaySARS‐CoV‐2therapeutics |
| spellingShingle | Anastasia Polycarpou Mark Howard Conrad A Farrar Roseanna Greenlaw Giorgia Fanelli Russell Wallis Linda S Klavinskis Steven Sacks Rationale for targeting complement in COVID‐19 EMBO Molecular Medicine complement proteins COVID‐19 lectin pathway SARS‐CoV‐2 therapeutics |
| title | Rationale for targeting complement in COVID‐19 |
| title_full | Rationale for targeting complement in COVID‐19 |
| title_fullStr | Rationale for targeting complement in COVID‐19 |
| title_full_unstemmed | Rationale for targeting complement in COVID‐19 |
| title_short | Rationale for targeting complement in COVID‐19 |
| title_sort | rationale for targeting complement in covid 19 |
| topic | complement proteins COVID‐19 lectin pathway SARS‐CoV‐2 therapeutics |
| url | https://doi.org/10.15252/emmm.202012642 |
| work_keys_str_mv | AT anastasiapolycarpou rationalefortargetingcomplementincovid19 AT markhoward rationalefortargetingcomplementincovid19 AT conradafarrar rationalefortargetingcomplementincovid19 AT roseannagreenlaw rationalefortargetingcomplementincovid19 AT giorgiafanelli rationalefortargetingcomplementincovid19 AT russellwallis rationalefortargetingcomplementincovid19 AT lindasklavinskis rationalefortargetingcomplementincovid19 AT stevensacks rationalefortargetingcomplementincovid19 |